Molecular	JJ
targets	NNS
in	IN
pulmonary	JJ
fibrosis	NN
:	:
the	DT
myofibroblast	NN
in	IN
focus	NN
.	.

Idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
is	VBZ
one	CD
of	IN
a	DT
group	NN
of	IN
interstitial	JJ
lung	NN
diseases	NNS
that	WDT
are	VBP
characterized	VBN
by	IN
excessive	JJ
matrix	NN
deposition	NN
and	CC
destruction	NN
of	IN
the	DT
normal	JJ
lung	NN
architecture	NN
.	.

Long-term	JJ
survival	NN
of	IN
IPF	NN
patients	NNS
is	VBZ
poor	JJ
,	,
with	IN
a	DT
5-year	JJ
survival	NN
rate	NN
of	IN
only	RB
20	CD
%	NN
.	.

Despite	IN
a	DT
lack	NN
of	IN
evidence-based	JJ
benefit	NN
,	,
IPF	NN
has	VBZ
historically	RB
been	VBN
treated	VBN
with	IN
corticosteroids	NNS
and/or	CC
cytotoxic	JJ
agents	NNS
such	JJ
as	IN
prednisone	NN
.	.

Given	VBN
the	DT
poor	JJ
efficacy	NN
of	IN
these	DT
drugs	NNS
,	,
novel	JJ
therapeutic	JJ
strategies	NNS
are	VBP
required	VBN
for	IN
the	DT
management	NN
of	IN
IPF	NN
.	.

This	DT
demands	VBZ
a	DT
better	JJR
understanding	NN
of	IN
the	DT
molecular	JJ
mechanisms	NNS
underlying	VBG
the	DT
pathogenesis	NN
and	CC
progression	NN
of	IN
this	DT
disease	NN
.	.

The	DT
primary	JJ
effector	NN
cell	NN
in	IN
fibrosis	NN
is	VBZ
the	DT
myofibroblast	NN
;	:
these	DT
cells	NNS
are	VBP
highly	RB
synthetic	JJ
for	IN
collagen	NN
,	,
have	VBP
a	DT
contractile	JJ
phenotype	NN
,	,
and	CC
are	VBP
characterized	VBN
by	IN
the	DT
presence	NN
of	IN
alpha-smooth-muscle-actin	JJ
stress	NN
fibers	NNS
.	.

They	PRP
may	MD
be	VB
derived	VBN
by	IN
activation/proliferation	NN
of	IN
resident	JJ
lung	NN
fibroblasts	NNS
,	,
epithelial-mesenchymal	JJ
differentiation	NN
,	,
or	CC
recruitment	NN
of	IN
circulating	VBG
fibroblastic	JJ
stem	NN
cells	NNS
(	(
fibrocytes	NNS
)	)
.	.

From	IN
a	DT
therapeutic	JJ
viewpoint	NN
,	,
interfering	VBG
with	IN
the	DT
pathways	NNS
that	WDT
lead	VBP
to	TO
myofibroblast	JJ
expansion	NN
should	MD
be	VB
of	IN
considerable	JJ
benefit	NN
in	IN
the	DT
treatment	NN
of	IN
IPF	NN
.	.

This	DT
review	NN
will	MD
highlight	VB
some	DT
of	IN
the	DT
key	JJ
molecules	NNS
involved	VBN
in	IN
this	DT
process	NN
and	CC
the	DT
clinical	JJ
trials	NNS
that	WDT
have	VBP
ensued	VBN
.	.

